Heron Therapeutics Continues To Expect FY24 Product Revenues, Net Of $138M - $158M (Est $147.855M), Narrows Guidance For Adjusted Operating Expenses, Adjusted EBITDA
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics has reaffirmed its FY24 product revenue expectations, net of $138M - $158M, with an estimated $147.855M. The company has also narrowed its guidance for adjusted operating expenses and adjusted EBITDA.
August 06, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Heron Therapeutics has reaffirmed its FY24 product revenue expectations, net of $138M - $158M, with an estimated $147.855M. The company has also narrowed its guidance for adjusted operating expenses and adjusted EBITDA.
Reaffirming revenue expectations and narrowing guidance for expenses and EBITDA are positive signals for investors, indicating stability and potential for meeting financial targets.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100